Proglumide, a non-selective antagonist of CCK1R and CCK2R, was used clinically for its analgesic properties in the 1980s [50,51,52] and is currently in a clinical trial (Phase I) for the management of nonalcoholic fatty liver disease (clinicaltrial.gov, NCT04152473). Here, CCKAR is linked to metabolic dysfunction-associated steatotic liver disease.